Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

被引：13
|
作者：
Rimassa, Lorenza
Cicin, Irfan
Blanc, Jean-Frederic
Klumpen, Heinz Josef
Zagonel, Vittorina
Tran, Albert
Kim, Stefano Chong Hun
Lin, Zhong-Zhe
Tam, Vincent C.
Hazra, Saswati
Mangeshkar, Milan
El-Khoueiry, Anthony
Cheng, Ann-Lii
Meyer, Tim
Kelley, Robin Kate
Abou-Alfa, Ghassan K.
机构：
[1] Humanitas Clin & Res Ctr, Rozzano, Italy
[2] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey
[3] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Oncol, Amsterdam, Netherlands
[5] Ist Oncol Veneto, IRCCS, Padua, Italy
[6] Grp Hosp Archet, Nice, France
[7] Univ Besancon, Ctr Hosp, Besancon, France
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[10] Exelixis Inc, San Francisco, CA USA
[11] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[12] Natl Taiwan Univ Hosp, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4090
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts).
    Rojas-Hernandez, Cristhiam Mauricio
    Patt, Yehuda Z.
    Fekrazad, M. Houman
    Steinberg, Kim A.
    Roach, Mary
    Lee, Fa-Chyi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including advanced hepatocellular carcinoma (HCC)
    Geissler, M.
    Nguyen, L. T.
    Chapel, S.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Abou-Alfa, G. K.
    Lacy, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 241 - 241
  • [43] Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen L.
    Lim, Ho Yeong
    Baron, Ari D.
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas
    Lougheed, Julie C.
    Milwee, Steven
    El-Khoueiry, Anthony B.
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    ESMO OPEN, 2020, 5 (04) : 1 - 9
  • [44] LINIFANIB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS: A PHASE 2 TRIAL
    Toh, Han-Chong
    Chen, Pei-Jer
    Carr, Brian I.
    Knox, Jennifer J.
    Gill, Sharlene
    Qian, Jiang
    Qin, Qin
    Ricker, Justin L.
    Carlson, Dawn M.
    Yong, Wei Peng
    HEPATOLOGY, 2010, 52 (04) : 1166A - 1166A
  • [45] Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).
    Escudier, Bernard J.
    Motzer, Robert J.
    Powles, Thomas
    Tannir, Nizar M.
    Davis, Ian D.
    Donskov, Frede
    Grunwald, Viktor
    Heng, Daniel Yick Chin
    Hutson, Thomas
    Melichar, Bohuslav
    Nosov, Dimitry
    Rini, Brian I.
    Salman, Pamela
    Sternberg, Cora N.
    Szczylik, Cezary
    Wolter, Pascal
    Arroyo, Alan M.
    Mangeshkar, Milan
    Agarwal, Neeraj
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [46] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard
    Par, Sumanta
    Kollmannsberger, Christian
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Markby, David W.
    Arroyo, Alan
    Dean, Mark
    Choueiri, Toni K.
    George, Daniel
    BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 663 - 669
  • [47] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Thomas Powles
    Robert J. Motzer
    Bernard Escudier
    Sumanta Pal
    Christian Kollmannsberger
    Joanna Pikiel
    Howard Gurney
    Sun Young Rha
    Se Hoon Park
    Poul F. Geertsen
    Marine Gross-Goupil
    Enrique Grande
    Cristina Suarez
    David W. Markby
    Alan Arroyo
    Mark Dean
    Toni K. Choueiri
    Daniel George
    British Journal of Cancer, 2018, 119 : 663 - 669
  • [48] Quality-adjusted life-years accrued with cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
    Strasser, S.
    Abou-Alfa, G.
    Mollon, P.
    Meyer, T.
    Cheng, A.
    El-Khoueiry, A.
    Kelley, R.
    Baron, A.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 43 - 43
  • [49] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
    Cheng, A.
    Kang, Y.
    Chen, Z.
    Tsao, C.
    Qin, S.
    Kim, J.
    Burock, K.
    Zou, J.
    Voliotis, D.
    Guan, Z. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
    Trojan, J.
    Abou-Alfa, G. K.
    Mollon, P.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Baron, A. D.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 241 - 241
12345